Prostate Cancer

A Comprehensive Portfolio of PSA Assays

Prostate cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall. There were 1.3 million new cases of prostate cancer in 2018.1 Siemens Healthineers offers a full menu of Prostate Specific Antigen (PSA) tests that aid in the detection, monitoring and management of prostate cancer. In addition to traditional PSA tests, the Siemens Healthineers portfolio includes the unique Complexed PSA assay that is an alternative to conventional testing and can improve the detection of clinically significant cancers.

PSA testing is a classic screening method to aid in the detection of prostate cancer and is clinically accepted by the NACB and EGTM for both detection and monitoring.2 Siemens Healthineers offers the following PSA assays:

PSA Assay: Intended for the measurement of serum PSA, in conjunction with a digital rectal exam (DRE), as an aid in the detection of prostate cancer in men aged 50 years and older. This assay is further indicated as an aid in the management (monitoring) of patients with prostate cancer.

Free PSA (fPSA) Assay: Intended to be used in conjunction with the Atellica® IM PSA Assay in men aged 50 years or older with total PSA values between 4 and 10 ng/mL and a digital rectal exam (DRE) non‑suspicious for cancer to determine the percent free PSA value. The percent free PSA value can be used as an aid in discriminating between prostate cancer and benign prostatic disease.

Complexed PSA (cPSA) Assay: Intended for the measurement of serum‑complexed PSA in conjunction with digital rectal exam (DRE) as an aid in the detection of prostate cancer in men aged 50 years or older. PSA complexed with alpha-1-antichymotrypsin (ACT) comprises a higher proportion of PSA in men with prostate cancer.3-5 This assay is further indicated as an aid in the management (monitoring) of prostate cancer patients.

Siemens Healthineers PSA Assay Benefits

  • Reduce unnecessary biopsies by using an assay that helps to discriminate between prostate cancer and benign prostatic diseases.5-7
  • Achieve accurate results with improved specificity in the detection of prostate cancer.4,5,7
  • Improve patient management with information on possible disease relapse.

PSA system availability: Atellica® IM Analyzer, ADVIA Centaur® CP/ XP/XPT Immunoassay systems, Dimension Vista® Systems, and IMMULITE® 2000/2000 XPi Immunoassay System.
fPSA system availability: Atellica® IM Analyzer, ADVIA Centaur® XP/XPT Immunoassay systems, Dimension Vista® Systems, and IMMULITE® 2000/2000 XPi Immunoassay System.
cPSA system availability: Atellica® IM Analyzer and ADVIA Centaur® CP/ XP/XPT Immunoassay systems

1

2

3

4

5

6

7

8